CRISPR therapy targets Hard-to-Treat lung cancer liver tumors
NCT ID NCT07461727
First seen Mar 22, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This early-stage study tests a new gene-editing drug called EDB-102 in 15 adults with advanced non-small cell lung cancer that has spread to the liver and is no longer responding to standard targeted therapy. The drug uses CRISPR technology to find and disable a specific cancer-causing gene mutation (EGFR L858R) in tumor cells. The main goals are to check the drug's safety and find the best dose, while also seeing if it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.